Saito T.,Nippon Medical School |
Saito T.,Toranomon Hospital Endocrine Center |
Miura D.,Endocrine Surgery |
Miura D.,Okinaka Memorial Institute for Medical Research |
And 7 more authors.
American Journal of the Medical Sciences | Year: 2010
Medullary thyroid carcinoma (MTC) occurs as a part of multiple endocrine neoplasia (MEN) type 2. Acromegaly, a pituitary adenoma, occurs as a part of MEN1. Rarely, MEN2 and MEN1 coexist in a single patient simultaneously. A 40-year-old man with a history of pituitary adenomectomy for acromegaly had a surgical resection of thyroid carcinoma clinically diagnosed as MTC. His mother, who had MTC and pheochromocytoma, had a germline mutation in the RET gene that could cause the subtype, MEN2A. Identification of gene mutations in RET and MEN1 were examined in the subject. The resected tumor was pathologically diagnosed as MTC. Genomic examinations revealed the RET mutation C634F, which was identical to the mutation of his mother, but no MEN1 gene mutation was found. Although the simultaneous occurrence of both MEN2A and sporadic acromegaly may be accidental, there is evidence to suggest a genetic interaction between MEN2 and acromegaly. © Copyright 2010 Southern Society for Clinical Investigation. Source
Vaira V.,Fondazione IRCCS Ca Granda ospedale Maggiore Policlinico |
Elli F.,Endocrinology Unit |
Elli F.,University of Milan |
Forno I.,University of Milan |
And 10 more authors.
Journal of Molecular Endocrinology | Year: 2012
A subset of over-expressed microRNAs (miRNAs) identified in parathyroid carcinomas (Ca) compared to normal glands belongs to C19MC, a cluster on chromosome 19q13.4 involved in stem cell biology and tumourigenesis. In this study, the expression of C19MC-MIR371-3 clusters and the molecular mechanisms presiding their modulation were investigated in a series of six normal parathyroids, 24 adenomas (Ad), 15 Ca and five matched metastases. The general expression levels of C19MC or MIR371-3 clusters in Ad lesions did not differ from normal glands, while they distinguished Ad from Ca at unsupervised hierarchical cluster analysis (P=0·0008). MIR517C showed the most significant difference in expression between Ca and Ad (P=0·0003) and it positively correlated with serum calcium, parathormone and tumour weight. In regard to the molecular mechanism determining C19MC cluster activation, we could detect C19MC copy number (CN) gain in ten Ca (67%) extending distal to the MIR371-3 cluster in almost all samples. Conversely, only four Ad (16%) showed C19MC amplification, with one case presenting distal genomic aberration to MIR371-3. Globally, CN variations of 19q13.4 loci were significantly associated with MIR517C up-regulation (P=0·006). Opposite to normal glands where C19MC promoter was methylated, hypomethylation occurred in 15 out of 30 analysed tumours. Though the epigenetic status did not correlate with C19MC miRNA expression levels, loss of C19MC promoter methylation was significantly associated with Ca and metastatic disease (P=0·01). In conclusion, C19MC cluster aberrations are a characteristic of Ca with respect to Ad. Altogether, these evidences point towards a role for 19q13.4 miRNA clusters as oncogenes in parathyroid tumourigenesis. © 2012 Society for Endocrinology. Source
Corbetta S.,University of Milan |
Vaira V.,University of Milan |
Guarnieri V.,Unit of Medical Genetics |
Scillitani A.,Unit of Endocrinology |
And 8 more authors.
Endocrine-Related Cancer | Year: 2010
Parathyroid carcinoma (PaC) is a rare cause of primary hyperparathyroidism. Though the loss of the oncosuppressor CDC73/HRPT2 gene product, parafibromin, has been involved in the hyperparathyroidism-jaw tumor syndrome and in a consistent set of sporadic PaCs, parathyroid carcinogenesis remains obscure. MicroRNAs are a new class of small, non-coding RNAs implicated in development of cancer, since their deregulation can induce aberrant expression of several target genes. The aim of the present study was to identify differentially expressed microRNAs in parathyroid cancers compared with normal tissues. We performed a TaqMan low-density array profiling of four parathyroid cancers harboring CDC73 inactivating mutations and negative for parafibromin immunostaining. Their microRNA profiling was compared with that of two normal parathyroid biopsies. Out of 362 human microRNAs assayed, 279 (77%) were successfully amplified. Fourteen and three microRNAs were significantly down- and over-expressed in parathyroid cancers respectively. Of these, miR-296 and miR-139 were down-regulated, and miR-503 and miR-222 were over-expressed with a null false discovery rate. Carcinomas could be discriminated from parathyroid adenomas by a computed score based on the expression levels of miR-296, miR-222, and miR-503 as miR-139 was similarly down-regulated in both cancers and adenomas. Finally, miR-296 and miR-222 levels negatively correlated with mRNA levels of the hepatocyte growth factor receptor-regulated tyrosine kinase substrate and p27/kip1 levels respectively. These results suggest the existence of an altered microRNA expression pattern in PaCs together with a potential role of miR-296 as novel oncosuppressor gene in these neoplasia. © 2010 Society for Endocrinology Printed in Great Britain. Source
Palazzo F.,Endocrine Surgery |
Dickinson A.,Plymouth Hospitals NHS Trust |
Phillips B.,St. Georges Hospital |
Sahdev A.,St. Bartholomews Hospital |
And 4 more authors.
Clinical Endocrinology | Year: 2016
Aims and Background Adrenal surgery is performed by a variety of surgical specialities in differing environments and volumes. International data suggest that there is a correlation between adrenal surgery volume and outcomes but there are no UK data to support this or UK surgical guidelines. A multidisciplinary team representing the stakeholders in adrenal disease is preparing a national guidance on adrenal surgery. A review of the outcomes for adrenal surgery in England was performed to correlate outcomes with the volume of surgeon practice. Methods Hospital Episode Statistics (HES) data for the National Health Service (NHS) in England in the tax year 2013-2014 were examined for adrenal surgery. Length of hospital stay and rate of postoperative readmission were assessed as surrogate quality markers and a comparison made between 'high-' and 'low-' volume surgeons. Results A total of 795 adult adrenalectomies were performed by 222 different surgeons with a range of between 1 and 34 adrenalectomies performed per surgeon. Only thirty-six (16%) adrenal surgeons performed 6 or more adrenalectomies. A total of 186 surgeons (84%) performed a median of one adrenalectomy a year. Length of stay and readmission rate within thirty days of operation was 60% longer and 47% higher, respectively, when performed by low-volume surgeons. Conclusion The current provision of adrenal surgery in the UK is not in the best interests of patients and is not cost-effective for the NHS. Adrenal surgery is best performed by higher volume surgeons in centres with dedicated adrenal multidisciplinary teams expert in all aspects of care of the adrenal patient. © 2016 John Wiley & Sons Ltd. Source
Rosato L.,ASL TO 4 Ivrea Hospital TO |
Raffaelli M.,Catholic University |
Bellantone R.,Catholic University |
Pontecorvi A.,Catholic University |
And 21 more authors.
Journal of Endocrinological Investigation | Year: 2014
Aim: To update the Diagnostic-Therapeutic-Healthcare Protocol (Protocollo Diagnostico-Terapeutico-Assistenziale, PDTA) created by the U.E.C. CLUB (Association of the Italian Endocrine Surgery Units) during the I Consensus Conference in 2008. Methods: In the preliminary phase, the II Consensus involved a selected group of experts; the elaboration phase was conducted via e-mail among all members; the conclusion phase took place during the X National Congress of the U.E.C. CLUB. The following were examined: diagnostic pathway and clinical evaluation; mode of admission and waiting time; therapeutic pathway (patient preparation for surgery, surgical treatment, postoperative management, management of major complications); hospital discharge and patient information; outpatient care and follow-up. Conclusions: The PDTA for parathyroid surgery approved by the II Consensus Conference (June 2013) is the official PDTA of the U.E.C. CLUB. © Italian Society of Endocrinology (SIE) 2013. Source